Atorvastatin n= 49 | Placebo n= 51 | P-value | |
---|---|---|---|
Age, years, mean (SD) | 62.8 (21.2) | 64 (15.6) | 0.745 |
Male gender, % | 51 | 51 | 0.570 |
Scoring systems | |||
MEWS, mean (SD) | 2.8 (2.1) | 3.3 (2.1) | 0.197 |
APACHE II, mean (SD) | 11.8 (5.6) | 11.9 (6.0) | 0.914 |
Predicted mortality, median (IQR) | 14.6 (8.7, 23.5) | 12.9 (7.6, 26.2) | 0.909 |
Biochemical data | |||
Cholesterol, mmol/L, median (IQR) | 4.0 (2.9, 5.1) | 4.35 (3.35, 5.35) | 0.505 |
Neutrophils, × 109/L median (IQR) | 11.6 (8.3, 13.7) | 12.4 (9.3, 19.4) | 0.232 |
C-reactive protein, mg/L, mean (SD) | 194.6 (114.6) | 188.0 (127.3) | 0.683 |
Source of infection, number of cases | |||
Pneumonia | 27 | 24 | 0.674 |
Urinary tract | 8 | 9 | 0.808 |
Cellulitis | 6 | 10 | 0.317 |
Gastrointestinal | 5 | 7 | 0.563 |
Bacteraemia | 2 | 1 | 0.563 |
Urinary catheter | 1 | 0 | 0.317 |
Antibiotic therapy, number of patients | 38 | 42 | 0.654 |
Co-morbidities, number of patients | |||
0 | 15 | 17 | 0.832 |
1 | 22 | 21 | 0.840 |
2 | 7 | 6 | 0.772 |
3 or more | 5 | 8 | 0.554 |
Number of trial drug doses, median (IQR) | 3 (2, 7) | 5 (2, 8) | 0.322 |